MX2022012234A - Inhibidores de la caspasa para mejorar la reparación de lesiones y para tratar infecciones bacterianas o virales. - Google Patents

Inhibidores de la caspasa para mejorar la reparación de lesiones y para tratar infecciones bacterianas o virales.

Info

Publication number
MX2022012234A
MX2022012234A MX2022012234A MX2022012234A MX2022012234A MX 2022012234 A MX2022012234 A MX 2022012234A MX 2022012234 A MX2022012234 A MX 2022012234A MX 2022012234 A MX2022012234 A MX 2022012234A MX 2022012234 A MX2022012234 A MX 2022012234A
Authority
MX
Mexico
Prior art keywords
viral infections
injury repair
treat bacterial
caspase inhibitors
caspase
Prior art date
Application number
MX2022012234A
Other languages
English (en)
Inventor
Mohameed Islam
Luis Garza
Lloyd Miller
Martin Alphonse
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2022012234A publication Critical patent/MX2022012234A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere al campo de la inhibición de la caspasa. Más específicamente, la presente invención proporciona composiciones y métodos que utilizan inhibidores de caspasa para mejorar la reparación de lesiones y tratar infecciones bacterianas y virales. En una modalidad específica, un método para tratar una infección bacteriana y lesiones cutáneas en un paciente comprende la etapa de administrar al paciente una cantidad eficaz de un inhibidor de caspasa.
MX2022012234A 2020-03-30 2021-03-30 Inhibidores de la caspasa para mejorar la reparación de lesiones y para tratar infecciones bacterianas o virales. MX2022012234A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063001674P 2020-03-30 2020-03-30
PCT/US2021/024889 WO2021202530A1 (en) 2020-03-30 2021-03-30 Caspase inhibitors to enhance injury repair and to treat bacterial and viral infections

Publications (1)

Publication Number Publication Date
MX2022012234A true MX2022012234A (es) 2023-01-16

Family

ID=77929521

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012234A MX2022012234A (es) 2020-03-30 2021-03-30 Inhibidores de la caspasa para mejorar la reparación de lesiones y para tratar infecciones bacterianas o virales.

Country Status (11)

Country Link
US (2) US20230218705A1 (es)
EP (1) EP4126010A4 (es)
JP (1) JP2023520460A (es)
KR (1) KR20230006480A (es)
CN (1) CN115551536A (es)
AU (1) AU2021245848A1 (es)
BR (1) BR112022019850A2 (es)
CA (1) CA3174364A1 (es)
IL (1) IL296890A (es)
MX (1) MX2022012234A (es)
WO (1) WO2021202530A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4135845A2 (en) 2020-04-14 2023-02-22 Amerimmune, LLC Treatment for diseases caused by rna viruses
IT202300000834A1 (it) 2023-01-20 2024-07-20 Scylla Biotech Srl Inibitori selettivi della caspasi-8 ed usi degli stessi per potenziare le difese innate
CN116334213B (zh) * 2023-04-03 2026-04-07 上海市东方医院(同济大学附属东方医院) circ-0007527作为靶点在筛选用于治疗腹膜透析相关腹膜纤维化的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03009647A (es) * 2001-04-19 2004-01-29 Vertex Pharma Heterociclildicarbamidas como inhibidores de caspasa.
AU2007207434B2 (en) * 2006-01-20 2012-04-05 Reneuron, Inc. Method of improving cell proliferation of pancreatic progenitor cells in a pancreatic cell culture
FR2923160B1 (fr) * 2007-11-02 2013-07-26 Pasteur Institut Composes destines a prevenir ou traiter une infection virale.
US10105305B2 (en) * 2014-02-19 2018-10-23 The Johns Hopkins University Compositions and methods for promoting skin regeneration and hair growth
KR20180101418A (ko) * 2015-12-31 2018-09-12 코나터스 파마슈티칼스, 인크. 간 질환의 치료에서의 카스파제 억제제의 사용 방법
IL248468A0 (en) * 2016-10-13 2017-01-31 Technion Res & Dev Foundation Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing
EP3609523B1 (en) * 2017-04-24 2022-03-02 Tsinghua University Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy
AU2019359473B2 (en) * 2018-10-11 2025-11-20 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for cell culture
WO2022008597A1 (en) * 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases

Also Published As

Publication number Publication date
CA3174364A1 (en) 2021-10-07
EP4126010A4 (en) 2024-04-24
US20240115649A1 (en) 2024-04-11
US20230218705A1 (en) 2023-07-13
CN115551536A (zh) 2022-12-30
IL296890A (en) 2022-12-01
BR112022019850A2 (pt) 2023-04-25
KR20230006480A (ko) 2023-01-10
JP2023520460A (ja) 2023-05-17
WO2021202530A1 (en) 2021-10-07
AU2021245848A1 (en) 2022-12-01
EP4126010A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
MX2024000271A (es) Inhibidor de shp2 y uso del mismo.
WO2020205473A8 (en) Compositions and methods for the treatment of kras associated diseases or disorders
MX2018015516A (es) Inhibidores de papd5 y papd7 para tratar la infeccion por hepatitis b.
BR9916785A (pt) Tratamento de asma com inibidores mek
EA202192528A1 (ru) Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
MX2023012095A (es) Inhibidores de hdac6 para el uso en el tratamiento de la miocardiopatía dilatada.
BR112022019850A2 (pt) Inibidores de caspase para melhorar o reparo de lesões e para tratar infecções bacterianas e virais
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
PH12022553501A1 (en) Alk2 inhibitors for the treatment of anemia
MX2022000545A (es) Inhibidores de enzimas.
MX2024014121A (es) Metodos y composiciones para el tratamiento del exceso de glucocorticoides
BR112022013646A2 (pt) Método de tratamento de esplenomegalia
MX2025010157A (es) Metodo de preparacion y uso de un derivado de dihidrotienopirimidina
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
WO2023164455A3 (en) Compositions and methods to modulate the immune system
PH12019500242A1 (en) 9-aminomethyl minocycline compounds and uses thereof
MX2024015040A (es) Fitusiran para el tratamiento de la hemofilia a y b en pacientes pediatricos
WO2020201833A8 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2025006279A (es) Tratamientos contra el cancer mediante un inhibidor de prmt5 y un inhibidor de mat2a
MX2023006704A (es) Composiciones dsg2 y metodos para el tratamiento de covid-19.